Pharmaceutical classification with the regulatory record attached
Connect chemical identity, presentation, intended use, tariff treatment, and the FDA or DEA pathway that applies to the actual shipment.
Reviewed July 31, 2026. This page is a workflow guide, not an admissibility determination. Verify the product, establishment, application, controlled-substance, and entry facts with FDA, DEA, and CBP.
Classification workflow
Bulk chemical, API, or finished medicament?
Pharmaceutical supply chains can cross Chapters 28, 29, 30, 38, and 90. Chemical identity, mixture composition, measured-dose presentation, therapeutic use, and product form determine the classification path.
Chemical identity and form
Record the active moiety, salt or derivative, CAS number, purity, mixture composition, dosage form, and whether ingredients are presented in measured doses.
Intended use
Distinguish a bulk chemical, active pharmaceutical ingredient, excipient, diagnostic reagent, finished medicament, clinical-trial article, or device component.
Product authorization data
Retain manufacturer, establishment registration, drug listing, application or investigational reference when applicable, labeling, and intended consignee.
Controlled-substance status
Confirm the precise substance, schedule, narcotic status, quantity, registrant authority, and transaction type before choosing a DEA permit or declaration path.
FDA
Registration and listing are not the same as a DMF
Foreign establishments that manufacture, repack, relabel, or salvage imported human drugs generally must register, and commercially distributed drugs generally must be listed. A marketing or investigational application may also be required for the product. Drug Master Files are optional submissions: FDA states that they are not required by statute or regulation and reviews them only in connection with an application that references them. FDA prior notice is a food requirement, not a universal requirement for human drug imports.
DEA
The filing route depends on the substance
DEA does not use one permit rule for every Schedule I-V shipment. Form DEA-357 is the import-permit route for Schedule I or II substances and specified narcotic or designated substances in Schedules III-V. Eligible nonnarcotic Schedule III-V imports generally use the DEA-236 declaration process, which includes advance-notice requirements. Only DEA-registered and authorized importers may submit these filings.
DEA import and export guidanceCurrent tariff context
Verify the product-specific exemption—not a “pharma” label
Legacy China Section 301 duties can apply to covered chemicals and intermediates. The forced-labor Section 301 action effective July 24, 2026 also covers 60 economies, but enumerated pharmaceutical-use products and other listed articles may be exempt.
Treatment can be additive, capped net of MFN, or exempt. A product being used in pharmaceutical manufacturing does not by itself establish an exemption; match the exact HTS line and conditions.
Tools for pharmaceutical teams
Current HTS lookup
Distinguish chemical and pharmaceutical headings and review the exact rate and special-provision text.
Explore toolLive duty calculation
Verify base and Chapter 99 treatment without assuming that a broad pharmaceutical category is duty-free.
Explore toolRegulatory research
Research FDA and DEA questions from official sources and keep the analysis with the product record.
Explore tool